MagicDiligence
Back to screen

Zevra Therapeutics Inc (ZVRA)

Generated: August 15, 2026
❌ Fail

Business Overview

Zevra Therapeutics Inc is a commercial-stage rare disease biopharma company focused on therapies for conditions with limited or no treatment options.[1][5][9] It generates revenue from product sales, primarily OLPRUVA for urea cycle disorders and an approved therapy for Niemann-Pick disease type C, and from royalties and milestones on AZSTARYS, a once-daily ADHD treatment licensed to partner Corium.[1][3][5][9] Additional value comes from a late-stage pipeline including KP1077 for idiopathic hypersomnia and narcolepsy and celiprolol for vascular Ehlers-Danlos syndrome.[1][3][6][9]

Non-Recurring Revenue

Zevra’s reported revenue in 2023 was materially boosted by one-time milestone payments under its AZSTARYS license agreement. In its March 28, 2024 full-year 2023 release, the company disclosed that period-over-period revenue growth was driven by an $18.5 million increase in royalties and milestones, including $15 million of one-time net sales milestone payments earned in FY 2023.[8] These milestones are contractually possible in future years but are inherently non-recurring in timing and size, and depend on partner sales thresholds.[8] For investors using mechanical screens like the Magic Formula, this creates a distortion: 2023 revenue and earnings overstate sustainable run-rate performance because they incorporate a sizable windfall that is unlikely to repeat annually.[8]

Short-Seller & Fraud Risk

Public information does not indicate that Zevra is currently the subject of major short-seller campaigns or detailed fraud reports by dedicated short-selling firms. Recent company and market commentary frame it as a clinical and commercial rare-disease play rather than a classic “battleground stock.”[1][3][11] There are no widely reported accounting irregularities or regulatory fraud investigations tied specifically to its financial reporting in the last year based on available disclosures and mainstream profiles.[1][4][11] While short interest data fluctuate and may not be fully visible intraday, Zevra does not appear to have the combination of >15% short interest plus active activist short campaigns that would typically define a high-profile battleground name.[11]

Financial Health

Zevra is still a development-heavy biopharma and is not a mature, consistently cash-generative pharmaceutical company. Its business model relies on a mix of product sales, royalties/milestones, and external capital to support R&D and commercialization.[1][3][4][9] The latest 10-Q and company commentary continue to describe it as commercial-stage but investment-oriented, implying ongoing operating losses or modest profitability as pipeline spending remains high.[4] While specific debt balances and near-term maturities are not fully summarized in the public snapshots consulted, there are no prominent headlines about imminent debt distress, covenant breaches, or credit downgrades.[4][11][15] However, like most small- to mid-cap biotech firms, Zevra is dependent on access to capital markets or partnering deals to comfortably fund trials and potential launches over the next 12–24 months.[3][4][15]

Cyclicality Risk

Zevra operates in biotechnology and rare-disease therapeutics, which are generally not cyclical in the same way as commodities, autos, or semiconductors. Demand for treatments addressing serious rare conditions such as Niemann-Pick disease type C, urea cycle disorders, and idiopathic hypersomnia is driven by medical need rather than macroeconomic cycles.[1][5][9][14] Revenue volatility is more related to clinical, regulatory, and commercialization milestones—for example, approval events, launch ramps, and milestone payments—than to economic expansions or recessions.[3][8] As a result, there is no clear evidence that current revenue or margins are “peak cycle” in a cyclical sense; instead, investors should focus on pipeline execution, payer access, and uptake curves, not traditional industrial mean-reversion.[1][3][9]

The report fails primarily on Non-Recurring Revenue: FY 2023 results were significantly inflated by a $15 million one-time AZSTARYS milestone, distorting run-rate profitability for screening purposes.[8] While there are no major fraud or short-seller red flags, investors must adjust financials for this windfall when assessing valuation and quality.

Sources

  1. https://finance.yahoo.com/quote/ZVRA/
  2. https://zevra.com/
  3. https://umbrex.com/resources/company-profiles/zevra-therapeutics/
  4. https://investors.zevra.com/static-files/ba885254-2066-4a69-971c-e7809da0930c
  5. https://www.marketwatch.com/investing/stock/zvra/company-profile
  6. https://www.investing.com/equities/kempharm-inc-company-profile
  7. https://www.linkedin.com/company/zevratherapeutics
  8. https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-reports-fourth-quarter-and-full-year-2023
  9. https://zevra.com/the-zevra-story/
  10. https://sg.finance.yahoo.com/quote/ZVRA/profile/
  11. https://www.marketbeat.com/stocks/NASDAQ/ZVRA/
  12. https://www.zoominfo.com/c/zevra-therapeutics/566142485
  13. https://www.bloomberg.com/profile/company/KMPH:US
  14. https://www.massbio.org/members/zevra-therapeutics/
  15. https://pitchbook.com/profiles/company/61677-55

Featured in MagicDiligence Analysis